FADS2 is a key enzyme in synthesizing arachidonic acid (C20:4 omega-6) from linoleic acid (C18:2 omega-6), and the activity of FADS2 in the plasma has been found to be higher in patients with NAFLD than in healthy participants [34]. Here, FADS2 is linked to metabolic dysfunction-associated steatotic liver disease.